Literature DB >> 17517756

Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

A Gonzalez1, H Maradit Kremers, C S Crowson, K V Ballman, V L Roger, S J Jacobsen, W M O'Fallon, S E Gabriel.   

Abstract

OBJECTIVE: To compare the frequency of traditional cardiovascular (CV) risk factors in rheumatoid arthritis (RA) compared to non-RA subjects, and examine their impact on the risk of developing selected CV events (myocardial infarction (MI), heart failure (HF) and CV death) in these two groups.
METHODS: We examined a population-based incidence cohort of subjects with RA (defined according to the 1987 American College of Rheumatology criteria), and an age- and sex-matched non-RA cohort. All subjects were followed longitudinally through their complete community medical records, until death, migration, or 1 January 2001. Clinical CV risk factors and outcomes were defined using validated criteria. The chi2 test was used to compare the frequency of each CV risk factor at baseline. Person-years methods were used to estimate the rate of occurrence of each CV risk factor during follow-up. Cox models were used to examine the influence of CV risk factors on the development of CV outcomes.
RESULTS: A total of 603 RA and 603 non-RA subjects (73% female; mean age 58 years) were followed for a mean of 15 and 17 years (total: 8842 and 10,101 person-years), respectively. At baseline, RA subjects were significantly more likely to be former or current smokers when compared to non-RA subjects (p<0.001). Male gender, smoking, and personal cardiac history had weaker associations with CV events among RA subjects, compared to non-RA subjects. There was no significant difference between RA and non-RA subjects in the risk imparted with respect to the other CV risk factors (ie, family cardiac history, hypertension, dyslipidaemia, body mass index, or diabetes mellitus).
CONCLUSION: While some traditional CV risk factors imparted similar risk among RA compared with non-RA subjects, others (ie, male gender, smoking and personal cardiac history) imparted significantly less risk for the development of CV disease. These differences in the overall impact of traditional CV risk factors suggest that strategies to prevent CV disease and mortality focused solely on controlling traditional CV risk factors may be relatively less beneficial in RA subjects than in the general population. Further research is needed to determine optimal approaches to reducing CV morbidity and mortality in persons with RA.

Entities:  

Mesh:

Year:  2007        PMID: 17517756     DOI: 10.1136/ard.2006.059980

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  109 in total

1.  Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.

Authors:  Jeffrey R Curtis; Ani John; Onur Baser
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-09       Impact factor: 4.794

2.  Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis.

Authors:  Daniel H Solomon; Thorvardur Jon Love; Claire Canning; Sebastian Schneeweiss
Journal:  Ann Rheum Dis       Date:  2010-06-28       Impact factor: 19.103

3.  Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases.

Authors:  Laura R Rekedal; Elena Massarotti; Rajesh Garg; Radhika Bhatia; Timothy Gleeson; Bing Lu; Daniel H Solomon
Journal:  Arthritis Rheum       Date:  2010-12

Review 4.  Selection bias in rheumatic disease research.

Authors:  Hyon K Choi; Uyen-Sa Nguyen; Jingbo Niu; Goodarz Danaei; Yuqing Zhang
Journal:  Nat Rev Rheumatol       Date:  2014-04-01       Impact factor: 20.543

Review 5.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

6.  Rheumatologist and Primary Care Management of Cardiovascular Disease Risk in Rheumatoid Arthritis: Patient and Provider Perspectives.

Authors:  Christie M Bartels; Tonya J Roberts; Karen E Hansen; Elizabeth A Jacobs; Andrea Gilmore; Courtney Maxcy; Barbara J Bowers
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-04       Impact factor: 4.794

7.  Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile?

Authors:  Banerjee Arnab; Ghosh Biswadip; Pande Arindam; Mandal Shyamash; Ghosh Anirban; Palui Rajan
Journal:  J Cardiovasc Dis Res       Date:  2013-06-18

Review 8.  Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis.

Authors:  Silvio Romano; Elisa Salustri; Piero Ruscitti; Francesco Carubbi; Maria Penco; Roberto Giacomelli
Journal:  Curr Rheumatol Rep       Date:  2018-11-05       Impact factor: 4.592

Review 9.  Rheumatoid arthritis and cardiovascular disease.

Authors:  Mary Chester M Wasko
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

10.  High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study.

Authors:  Hilal Maradit Kremers; Cynthia S Crowson; Terry M Therneau; Veronique L Roger; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.